Loading...

Gary Scott Leiserowitz

TitleProf/Chair
InstitutionUniversity of California Davis
DepartmentObstetrics and Gynecology
Address4860 Y Street Suite 2500
CA 95817
Phone916-734-6938
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Miyamoto S, Stroble CD, Taylor S, Hong Q, Lebrilla CB, Leiserowitz GS, Kim K, Ruhaak LR. Multiple Reaction Monitoring for the Quantitation of Serum Protein Glycosylation Profiles: Application to Ovarian Cancer. J Proteome Res. 2018 01 05; 17(1):222-233. PMID: 29207246.
      View in: PubMed
    2. Girda E, Huang EC, Leiserowitz GS, Smith LH. The Use of Endometrial Cancer Patient-Derived Organoid Culture for Drug Sensitivity Testing Is Feasible. Int J Gynecol Cancer. 2017 10; 27(8):1701-1707. PMID: 28683005.
      View in: PubMed
    3. Nielsen AA, Liyanage TA, Leiserowitz GS, Mayadev J. Optimal perioperative anesthesia management for gynecologic interstitial brachytherapy. J Contemp Brachytherapy. 2017 Jun; 9(3):216-223. PMID: 28725244.
      View in: PubMed
    4. Leiserowitz GS, Lin JF, Tergas AI, Cliby WA, Bristow RE. Factors Predicting Use of Neoadjuvant Chemotherapy Compared With Primary Debulking Surgery in Advanced Stage Ovarian Cancer-A National Cancer Database Study. Int J Gynecol Cancer. 2017 05; 27(4):675-683. PMID: 28328580.
      View in: PubMed
    5. Carney RP, Hazari S, Colquhoun M, Tran D, Hwang B, Mulligan MS, Bryers JD, Girda E, Leiserowitz GS, Smith ZJ, Lam KS. Multispectral Optical Tweezers for Biochemical Fingerprinting of CD9-Positive Exosome Subpopulations. Anal Chem. 2017 May 16; 89(10):5357-5363. PMID: 28345878.
      View in: PubMed
    6. Miyamoto S, Ruhaak LR, Stroble C, Salemi MR, Phinney B, Lebrilla CB, Leiserowitz GS. Glycoproteomic Analysis of Malignant Ovarian Cancer Ascites Fluid Identifies Unusual Glycopeptides. J Proteome Res. 2016 09 02; 15(9):3358-76. PMID: 27500424.
      View in: PubMed
    7. Wallace SK, Lin JF, Cliby WA, Leiserowitz GS, Tergas AI, Bristow RE. Refusal of Recommended Chemotherapy for Ovarian Cancer: Risk Factors and Outcomes; a National Cancer Data Base Study. J Natl Compr Canc Netw. 2016 05; 14(5):539-50. PMID: 27160232.
      View in: PubMed
    8. Ruhaak LR, Kim K, Stroble C, Taylor SL, Hong Q, Miyamoto S, Lebrilla CB, Leiserowitz G. Protein-Specific Differential Glycosylation of Immunoglobulins in Serum of Ovarian Cancer Patients. J Proteome Res. 2016 Mar 04; 15(3):1002-10. PMID: 26813784.
      View in: PubMed
    9. Cress RD, Chen YS, Morris CR, Petersen M, Leiserowitz GS. Characteristics of Long-Term Survivors of Epithelial Ovarian Cancer. Obstet Gynecol. 2015 Sep; 126(3):491-7. PMID: 26244529; PMCID: PMC4545401.
    10. Kennedy VA, Leiserowitz GS. Preserving sexual function in women and girls with cancer: survivorship is about more than just surviving. Am J Obstet Gynecol. 2015 Aug; 213(2):119-20. PMID: 26216177.
      View in: PubMed
    11. Huddleston A, Zhen S, Qi L, Rash D, Leiserowitz G, Mayadev J. The impact of a vaginal brachytherapy boost to pelvic radiation in stage III endometrial cancer. J Contemp Brachytherapy. 2015 Apr; 7(2):122-7. PMID: 26034492; PMCID: PMC4444456.
    12. Kim K, Ruhaak LR, Nguyen UT, Taylor SL, Dimapasoc L, Williams C, Stroble C, Ozcan S, Miyamoto S, Lebrilla CB, Leiserowitz GS. Evaluation of glycomic profiling as a diagnostic biomarker for epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2014 Apr; 23(4):611-21. PMID: 24557531; PMCID: PMC4230493.
    13. Taylor SL, Leiserowitz GS, Kim K. Accounting for undetected compounds in statistical analyses of mass spectrometry 'omic studies. Stat Appl Genet Mol Biol. 2013 Dec; 12(6):703-22. PMID: 24246290; PMCID: PMC3905689.
    14. Ruhaak LR, Taylor SL, Miyamoto S, Kelly K, Leiserowitz GS, Gandara D, Lebrilla CB, Kim K. Chip-based nLC-TOF-MS is a highly stable technology for large-scale high-throughput analyses. Anal Bioanal Chem. 2013 May; 405(14):4953-8. PMID: 23525540; PMCID: PMC3640767.
    15. Hua S, Williams CC, Dimapasoc LM, Ro GS, Ozcan S, Miyamoto S, Lebrilla CB, An HJ, Leiserowitz GS. Isomer-specific chromatographic profiling yields highly sensitive and specific potential N-glycan biomarkers for epithelial ovarian cancer. J Chromatogr A. 2013 Mar 01; 1279:58-67. PMID: 23380366.
      View in: PubMed
    16. Kronewitter SR, De Leoz ML, Strum JS, An HJ, Dimapasoc LM, Guerrero A, Miyamoto S, Lebrilla CB, Leiserowitz GS. The glycolyzer: automated glycan annotation software for high performance mass spectrometry and its application to ovarian cancer glycan biomarker discovery. Proteomics. 2012 Aug; 12(15-16):2523-38. PMID: 22903841; PMCID: PMC3567444.
    17. Rodriguez AO, Gonik AM, Zhou H, Leiserowitz GS, White RH. Venous thromboembolism in uterine cancer. Int J Gynecol Cancer. 2011 Jul; 21(5):870-6. PMID: 21666485.
      View in: PubMed
    18. Cress RD, Bauer K, O'Malley CD, Kahn AR, Schymura MJ, Wike JM, Stewart SL, Leiserowitz GS. Surgical staging of early stage epithelial ovarian cancer: results from the CDC-NPCR ovarian patterns of care study. Gynecol Oncol. 2011 Apr; 121(1):94-9. PMID: 21256581.
      View in: PubMed
    19. Kronewitter SR, de Leoz ML, Peacock KS, McBride KR, An HJ, Miyamoto S, Leiserowitz GS, Lebrilla CB. Human serum processing and analysis methods for rapid and reproducible N-glycan mass profiling. J Proteome Res. 2010 Oct 01; 9(10):4952-9. PMID: 20698584; PMCID: PMC2948646.
    20. Leiserowitz GS, Xing G, Parikh-Patel A, Cress R, Abidi A, Rodriguez AO, Dalrymple JL. Laparoscopic versus abdominal hysterectomy for endometrial cancer: comparison of patient outcomes. Int J Gynecol Cancer. 2009 Nov; 19(8):1370-6. PMID: 20009892; PMCID: PMC4357489.
    21. Kronewitter SR, An HJ, de Leoz ML, Lebrilla CB, Miyamoto S, Leiserowitz GS. The development of retrosynthetic glycan libraries to profile and classify the human serum N-linked glycome. Proteomics. 2009 Jun; 9(11):2986-94. PMID: 19452454; PMCID: PMC2758495.
    22. Barkauskas DA, An HJ, Kronewitter SR, de Leoz ML, Chew HK, de Vere White RW, Leiserowitz GS, Miyamoto S, Lebrilla CB, Rocke DM. Detecting glycan cancer biomarkers in serum samples using MALDI FT-ICR mass spectrometry data. Bioinformatics. 2009 Jan 15; 25(2):251-7. PMID: 19073586; PMCID: PMC2639011.
    23. Chan JK, Kapp DS, Shin JY, Osann K, Leiserowitz GS, Cress RD, O'Malley C. Factors associated with the suboptimal treatment of women less than 55 years of age with early-stage ovarian cancer. Gynecol Oncol. 2008 Jan; 108(1):95-9. PMID: 17949796.
      View in: PubMed
    24. Leiserowitz GS, Lebrilla C, Miyamoto S, An HJ, Duong H, Kirmiz C, Li B, Liu H, Lam KS. Glycomics analysis of serum: a potential new biomarker for ovarian cancer? Int J Gynecol Cancer. 2008 May-Jun; 18(3):470-5. PMID: 17655680; PMCID: PMC2581843.
    25. Chan JK, Kapp DS, Shin JY, Husain A, Teng NN, Berek JS, Osann K, Leiserowitz GS, Cress RD, O'Malley C. Influence of the gynecologic oncologist on the survival of ovarian cancer patients. Obstet Gynecol. 2007 Jun; 109(6):1342-50. PMID: 17540806.
      View in: PubMed
    26. An HJ, Miyamoto S, Lancaster KS, Kirmiz C, Li B, Lam KS, Leiserowitz GS, Lebrilla CB. Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer. J Proteome Res. 2006 Jul; 5(7):1626-35. PMID: 16823970.
      View in: PubMed
    27. Leiserowitz GS. Managing ovarian masses during pregnancy. Obstet Gynecol Surv. 2006 Jul; 61(7):463-70. PMID: 16787549.
      View in: PubMed
    28. Elliott KS, Borowsky ME, Malka ES, Scudder SA, Leiserowitz GS, Russell AH. Long-term results of maximally aggressive trimodality therapy in a high-risk subset of early-stage cervical cancer patients. J Reprod Med. 2006 May; 51(5):383-8. PMID: 16779984.
      View in: PubMed
    29. Leiserowitz GS, Xing G, Cress R, Brahmbhatt B, Dalrymple JL, Smith LH. Adnexal masses in pregnancy: how often are they malignant? Gynecol Oncol. 2006 May; 101(2):315-21. PMID: 16310839.
      View in: PubMed
    30. Rodriguez AO, Truskinovsky AM, Kasrazadeh M, Leiserowitz GS. Case report: Malignant peripheral nerve sheath tumor of the uterine cervix treated with radical vaginal trachelectomy. Gynecol Oncol. 2006 Jan; 100(1):201-4. PMID: 16182351.
      View in: PubMed
    31. Dalrymple JL, Gilbert WM, Leiserowitz GS, Cress R, Xing G, Danielsen B, Smith LH. Pregnancy-associated cervical cancer: obstetric outcomes. J Matern Fetal Neonatal Med. 2005 Apr; 17(4):269-76. PMID: 16147836.
      View in: PubMed
    32. O'Malley CD, Cress RD, Campleman SL, Leiserowitz GS. Survival of Californian women with epithelial ovarian cancer, 1994-1996: a population-based study. Gynecol Oncol. 2003 Dec; 91(3):608-15. PMID: 14675685.
      View in: PubMed
    33. Leiserowitz GS, Gumbs JL, Oi R, Dalrymple JL, Smith LH, Ryu J, Scudder S, Russell AH. Endometriosis-related malignancies. Int J Gynecol Cancer. 2003 Jul-Aug; 13(4):466-71. PMID: 12911723.
      View in: PubMed
    34. Cress RD, O'Malley CD, Leiserowitz GS, Campleman SL. Patterns of chemotherapy use for women with ovarian cancer: a population-based study. J Clin Oncol. 2003 Apr 15; 21(8):1530-5. PMID: 12697877.
      View in: PubMed